title: Gemifloxacin for community-acquired pneumonia.
abstract: BACKGROUND
  Newer fluoroquinolones have become an important therapeutic choice in the treatment of community-acquired pneumonia (CAP). Gemifloxacin is one of the newest members of this class of antibiotics and has performed favourably in this indication.
  
  
  OBJECTIVE
  To analyse the microbiological activity, pharmacokinetic/pharmacodynamic properties and clinical activity of gemifloxacin in CAP, as well as the safety reported in controlled clinical studies.
  
  
  METHODS
  Literature research of English publications in the last 10 years addressing all aspects of gemifloxacin in CAP.
  
  
  CONCLUSIONS
  Gemifloxacin is microbiologically the most active fluoroquinolone against Streptococcus pneumoniae--the leading pathogen of CAP. In several comparative studies gemifloxacin was highly effective and well tolerated in the treatment of mild-to-moderate severe CAP.
authors.affiliation: RCMS, Hohenzollerndamm 2, Ecke Bundesallee, D-10717 Berlin-Wilmersdorf, Germany. haloheck@zedat.fu-berlin.de
authors.forename: Hartmut M
authors.initials: HM
authors.lastname: Lode
authors.forename: Malina
authors.initials: M
authors.lastname: Schmidt-Ionas
authors.forename: Ralf
authors.initials: R
authors.lastname: Stahlmann
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017714:Community-Acquired Infections; D024841:Fluoroquinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000077735:Gemifloxacin; D006801:Humans; D009287:Naphthyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin